

Christopher P Leamon

List of Publications by Year
in descending order

Source: <https://exaly.com/author-pdf/11586353/publications.pdf>

Version: 2024-02-01

80
papers

6,319
citations

76326
40
h-index

74163
75
g-index

81
all docs

81
docs citations

81
times ranked

6441
citing authors

#	ARTICLE	IF	CITATIONS
1	A Novel Treatment for Glomerular Disease: Targeting the Activated Macrophage Folate Receptor with a Trojan Horse Therapy in Rats. <i>Cells</i> , 2021, 10, 2113.	4.1	2
2	Targeting folate receptor beta on monocytes/macrophages renders rapid inflammation resolution independent of root causes. <i>Cell Reports Medicine</i> , 2021, 2, 100422.	6.5	7
3	Pre-clinical studies of EC2629, a highly potent folate- receptor-targeted DNA crosslinking agent. <i>Scientific Reports</i> , 2020, 10, 12772.	3.3	5
4	Design and synthesis of a folate-receptor targeted diazepine-ring-opened pyrrolobenzodiazepine prodrug conjugate. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 126987.	2.2	6
5	Detecting Functional and Accessible Folate Receptor Expression in Cancer and Polycystic Kidneys. <i>Molecular Pharmaceutics</i> , 2019, 16, 3985-3995.	4.6	7
6	Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adaptors. <i>Nature Communications</i> , 2019, 10, 2681.	12.8	69
7	Prostate-Specific Membrane Antigen-Specific Antitumor Activity of a Self-Immolative Tubulysin Conjugate. <i>Bioconjugate Chemistry</i> , 2019, 30, 1805-1813.	3.6	22
8	Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy With Special Focus on Pediatric Malignancies. <i>Frontiers in Oncology</i> , 2019, 9, 151.	2.8	43
9	Folate receptors and transporters: biological role and diagnostic/therapeutic targets in cancer and other diseases. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 125.	8.6	72
10	Folate receptor-beta expression as a diagnostic target in human & rodent nonalcoholic steatohepatitis. <i>Toxicology and Applied Pharmacology</i> , 2019, 368, 49-54.	2.8	3
11	Phase I/II clinical trial of the targeted chemotherapeutic drug, folate-tubulysin, in dogs with naturally-occurring invasive urothelial carcinoma. <i>Oncotarget</i> , 2018, 9, 37042-37053.	1.8	12
12	Carbonic Anhydrase IX-Targeted Near-Infrared Dye for Fluorescence Imaging of Hypoxic Tumors. <i>Bioconjugate Chemistry</i> , 2018, 29, 3320-3331.	3.6	20
13	Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, F395-F405.	2.7	24
14	Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic. <i>Scientific Reports</i> , 2018, 8, 8943.	3.3	40
15	Abstract LB-109: Adaptor controlled CAR-T cell immunotherapy for treatment of folate receptor-alpha/beta positive solid and liquid tumors. , 2018, , .		2
16	Enhancing the therapeutic range of a targeted small-molecule tubulysin conjugate for folate receptor-based cancer therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1151-1160.	2.3	10
17	Latent Warheads for Targeted Cancer Therapy: Design and Synthesis of pro-Pyrrolobenzodiazepines and Conjugates. <i>Bioconjugate Chemistry</i> , 2017, 28, 2921-2931.	3.6	14
18	High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1998-2008.	4.1	13

#	ARTICLE	IF	CITATIONS
19	Development and validation of a UPLC-MS/MS method for the novel folate-targeted small molecule drug conjugate EC1456 and its metabolites in tumor homogenates from mice. Journal of Pharmaceutical and Biomedical Analysis, 2016, 122, 148-156.	2.8	3
20	Antiinflammatory Activity of a Novel Folic Acid Targeted Conjugate of the mTOR Inhibitor Everolimus. Molecular Medicine, 2015, 21, 584-596.	4.4	22
21	Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors. Therapeutic Advances in Medical Oncology, 2015, 7, 206-218.	3.2	85
22	Rational Combination Therapy of Vintafolide (EC145) with Commonly Used Chemotherapeutic Drugs. Clinical Cancer Research, 2014, 20, 2104-2114.	7.0	24
23	Folate receptor-targeted aminopterin therapy is highly effective and specific in experimental models of autoimmune uveitis and autoimmune encephalomyelitis. Clinical Immunology, 2014, 150, 64-77.	3.2	19
24	Assessment of folate receptor expression and folate uptake in multicentric lymphomas in dogs. American Journal of Veterinary Research, 2014, 75, 187-194.	0.6	3
25	The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resistance Updates, 2014, 17, 89-95.	14.4	301
26	Folate-Vinca Alkaloid Conjugates for Cancer Therapy: A Structure-Activity Relationship. Bioconjugate Chemistry, 2014, 25, 560-568.	3.6	50
27	Expression of functional folate receptors by human parathyroid cells. Surgery, 2013, 154, 1385-1393.	1.9	8
28	Targeting Folate Receptors to Treat Invasive Urinary Bladder Cancer. Cancer Research, 2013, 73, 875-884.	0.9	52
29	In Vitro and in Vivo Evaluation of an Innocuous Drug Cocktail To Improve the Quality of Folic Acid Targeted Nuclear Imaging in Preclinical Research. Molecular Pharmaceutics, 2013, 10, 967-974.	4.6	7
30	PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer. Journal of Clinical Oncology, 2013, 31, 4400-4406.	1.6	177
31	177Lu-EC0800 Combined with the Antifolate Pemetrexed: Preclinical Pilot Study of Folate Receptor Targeted Radionuclide Tumor Therapy. Molecular Cancer Therapeutics, 2013, 12, 2436-2445.	4.1	19
32	Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer. Pharmacogenomics and Personalized Medicine, 2013, 6, 113.	0.7	16
33	Folate-Conjugated Rapamycin Slows Progression of Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2012, 23, 1674-1681.	6.1	89
34	Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors. Journal of Clinical Oncology, 2012, 30, 4011-4016.	1.6	78
35	Engineering Folate-Drug Conjugates to Target Cancer: From Chemistry to Clinic. Bioconjugate Chemistry, 2012, 23, 1357-1369.	3.6	207
36	Abstract 3622: Predicting response to EC145 therapy using the folate receptor-specific radiodiagnostic imaging agent, 99mTc-EC20. , 2012, , .		2

#	ARTICLE	IF	CITATIONS
37	Reducing Undesirable Hepatic Clearance of a Tumor-Targeted Vinca Alkaloid via Novel Saccharopeptidic Modifications. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 336, 336-343.	2.5	42
38	Treatment of experimental adjuvant arthritis with a novel folate receptor-targeted folic acid-aminopterin conjugate. <i>Arthritis Research and Therapy</i> , 2011, 13, R56.	3.5	61
39	Tumor targeting using ⁶⁷ Ga-DOTA-Bz-folate – investigations of methods to improve the tissue distribution of radiofolates. <i>Nuclear Medicine and Biology</i> , 2011, 38, 715-723.	0.6	42
40	Acid mediated formation of an N-acyliminium ion from tubulysins: A new methodology for the synthesis of natural tubulysins and their analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 6778-6781.	2.2	16
41	Design and regioselective synthesis of a new generation of targeted therapeutics. Part 3: Folate conjugates of aminopterin hydrazide for the treatment of inflammation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 1202-1205.	2.2	16
42	Targeting Activated Macrophages Via a Functional Folate Receptor for Potential Treatment of Autoimmune/Inflammatory Disorders. , 2011, , 195-216.		3
43	Regioselective synthesis of folate receptor-targeted agents derived from epothilone analogs and folic acid. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 4578-4581.	2.2	37
44	Effects of the Antifolates Pemetrexed and CB3717 on the Tissue Distribution of ^{99m} Tc-EC20 in Xenografted and Syngeneic Tumor-Bearing Mice. <i>Molecular Pharmaceutics</i> , 2010, 7, 597-604.	4.6	28
45	Carbohydrate-Based Synthetic Approach to Control Toxicity Profiles of Folate~Drug Conjugates. <i>Journal of Organic Chemistry</i> , 2010, 75, 3685-3691.	3.2	40
46	Clinical Pharmacokinetics and Exposure~Toxicity Relationship of a Folate~Vinca</i> Alkaloid Conjugate EC145 in Cancer Patients. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 1467-1476.	2.0	67
47	Properties Influencing the Relative Binding Affinity of Pteroate Derivatives and Drug Conjugates Thereof to the Folate Receptor. <i>Pharmaceutical Research</i> , 2009, 26, 1315-1323.	3.5	27
48	Ligand~Targeted Delivery of Small Interfering RNAs to Malignant Cells and Tissues. <i>Annals of the New York Academy of Sciences</i> , 2009, 1175, 32-39.	3.8	70
49	Strategy to Prevent Drug-Related Hypersensitivity in Folate-Targeted Hapten Immunotherapy of Cancer. <i>AAPS Journal</i> , 2009, 11, 628-638.	4.4	12
50	In Vivo Structural Activity and Optimization Studies of Folate~Tubulysin Conjugates. <i>Molecular Pharmaceutics</i> , 2009, 6, 1518-1525.	4.6	60
51	Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part II: Folic acid conjugates of tubulysins and their hydrazides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4558-4561.	2.2	37
52	Low-Dose Radiation Potentiates the Therapeutic Efficacy of Folate Receptor~Targeted Hapten Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 559-566.	0.8	8
53	Chapter 7 Exploitation of the Folate Receptor in the Management of Cancer and Inflammatory Disease. <i>Vitamins and Hormones</i> , 2008, 79, 203-233.	1.7	65
54	Impact of High and Low Folate Diets on Tissue Folate Receptor Levels and Antitumor Responses Toward Folate-Drug Conjugates. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 327, 918-925.	2.5	65

#	ARTICLE	IF	CITATIONS
55	Folate Targeting Enables Durable and Specific Antitumor Responses from a Therapeutically Null Tubulysin B Analogue. <i>Cancer Research</i> , 2008, 68, 9839-9844.	0.9	86
56	Folate-targeted drug strategies for the treatment of cancer. <i>Current Opinion in Investigational Drugs</i> , 2008, 9, 1277-86.	2.3	57
57	Preclinical Evaluation of EC145, a Folate-Vinca Alkaloid Conjugate. <i>Cancer Research</i> , 2007, 67, 4434-4442.	0.9	161
58	Folate Receptor-Specific Antitumor Activity of EC131, a Folate-Maytansinoid Conjugate. <i>Cancer Research</i> , 2007, 67, 6376-6382.	0.9	70
59	An Assembly Concept for the Consecutive Introduction of Unsymmetrical Disulfide Bonds: A Synthesis of a Releasable Multidrug Conjugate of Folic Acid. <i>Journal of Organic Chemistry</i> , 2007, 72, 5968-5972.	3.2	32
60	Folate-Targeted Dinitrophenyl Hapten Immunotherapy: Effect of Linker Chemistry on Antitumor Activity and Allergic Potential. <i>Molecular Pharmaceutics</i> , 2007, 4, 695-706.	4.6	33
61	Preclinical Antitumor Activity of a Novel Folate-Targeted Dual Drug Conjugate. <i>Molecular Pharmaceutics</i> , 2007, 4, 659-667.	4.6	100
62	Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145. <i>International Journal of Cancer</i> , 2007, 121, 1585-1592.	5.1	77
63	Synthesis and Biological Evaluation of EC140: A Novel Folate-Targeted Vinca Alkaloid Conjugate. <i>Bioconjugate Chemistry</i> , 2006, 17, 1226-1232.	3.6	52
64	Folate-Mediated Delivery of Protein and Peptide Drugs into Tumors. , 2006, , 183-204.		9
65	Folate receptor specific anti-tumor activity of folate-mitomycin conjugates. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 229-236.	2.3	69
66	Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvincristine monohydrazone. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 5093-5096.	2.2	126
67	Preclinical pharmacokinetics, tissue distribution, and antitumor activity of a folate-hapten conjugate-targeted immunotherapy in hapten-immunized mice. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 3258-3267.	4.1	33
68	Receptor-Mediated Drug Delivery. , 2005, , 167-187.		3
69	Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. <i>Analytical Biochemistry</i> , 2005, 338, 284-293.	2.4	1,054
70	Synthesis and Biological Evaluation of EC72: A New Folate-Targeted Chemotherapeutic. <i>Bioconjugate Chemistry</i> , 2005, 16, 803-811.	3.6	78
71	Ligand Binding and Kinetics of Folate Receptor Recycling in Vivo: Impact on Receptor-Mediated Drug Delivery. <i>Molecular Pharmacology</i> , 2004, 66, 1406-1414.	2.3	211
72	Folate-targeted chemotherapy. <i>Advanced Drug Delivery Reviews</i> , 2004, 56, 1127-1141.	13.7	513

#	ARTICLE	IF	CITATIONS
73	Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. <i>Advanced Drug Delivery Reviews</i> , 2004, 56, 1161-1176.	13.7	225
74	Preclinical evaluation of (99m)Tc-EC20 for imaging folate receptor-positive tumors. <i>Journal of Nuclear Medicine</i> , 2004, 45, 857-66.	5.0	82
75	Folate-Liposome-Mediated Antisense Oligodeoxynucleotide Targeting to Cancer Cells: Evaluation in Vitro and in Vivo. <i>Bioconjugate Chemistry</i> , 2003, 14, 738-747.	3.6	163
76	Folate-Targeted Gene Transfer in Vivo. <i>Molecular Therapy</i> , 2002, 5, 739-744.	8.2	125
77	Synthesis and Biological Evaluation of EC20: A New Folate-Derived, 99mTc-Based Radiopharmaceutical. <i>Bioconjugate Chemistry</i> , 2002, 13, 1200-1210.	3.6	206
78	Folate-mediated targeting: from diagnostics to drug and gene delivery. <i>Drug Discovery Today</i> , 2001, 6, 44-51.	6.4	341
79	Folate-mediated Drug Delivery: Effect of Alternative Conjugation Chemistry. <i>Journal of Drug Targeting</i> , 1999, 7, 157-169.	4.4	77
80	Folate Copolymer-Mediated Transfection of Cultured Cells. <i>Bioconjugate Chemistry</i> , 1999, 10, 947-957.	3.6	105